Contrasting Haemonetics (HAE) & Invuity (IVTY)

Haemonetics (NYSE: HAE) and Invuity (NASDAQ:IVTY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

How to Become a New Pot Stock Millionaire

46.7% of Invuity shares are owned by institutional investors. 1.2% of Haemonetics shares are owned by insiders. Comparatively, 10.5% of Invuity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Haemonetics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Invuity has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Haemonetics and Invuity, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics 0 2 4 0 2.67
Invuity 0 0 4 0 3.00

Haemonetics presently has a consensus target price of $70.00, indicating a potential downside of 4.53%. Invuity has a consensus target price of $9.33, indicating a potential upside of 138.10%. Given Invuity’s stronger consensus rating and higher possible upside, analysts plainly believe Invuity is more favorable than Haemonetics.

Profitability

This table compares Haemonetics and Invuity’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics -1.94% 12.39% 7.66%
Invuity -100.75% -380.14% -74.74%

Valuation and Earnings

This table compares Haemonetics and Invuity’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Haemonetics $886.12 million 4.42 -$26.26 million $1.53 47.92
Invuity $39.62 million 2.31 -$39.91 million ($2.20) -1.78

Haemonetics has higher revenue and earnings than Invuity. Invuity is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats Invuity on 8 of the 12 factors compared between the two stocks.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Invuity Company Profile

Invuity, Inc., a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges. It offers various illuminated surgical devices, including Eikon LT Illuminated and Eikon illuminated retractor systems for breast oncology/oncoplastic/general/orthopedics surgeries; Saber Yankauer, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general surgeries; and Saber Frazier, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Eika illuminated retractor systems for anterior neck approaches comprising thyroid and cervical spine surgeries; Breiten illuminated retractor systems for spine surgeries; Eipex illuminated retractor systems for spine/orthopedic surgeries; Eivector illuminated and Eiberg Illuminated retractor systems for orthopedic surgeries; and Waveguide XT system, a drop-in intracavity illuminator for spine surgeries. Invuity, Inc. sells its devices through its direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply